Related Experiment Video
Updated: Feb 24, 2026

Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss
Published on: July 19, 2024
The pharmacological management of NAFLD in children and adolescents
Savinda Liyanagedera1, Robert Patrick Williams1, Silvio Veraldi2,3
1a Department of Paediatrics , Cardiff University School of Medicine , Cardiff , UK.
Introduction:
Non-alcoholic fatty liver disease (NAFLD) represents a spectrum, including 'simple' steatosis, non-alcoholic steatohepatitis (NASH), and fibrosis. Increasing prevalence of NAFLD has followed the international rise in obesity and lifestyle modification is the mainstay therapy for children. To date, pharmacological trials have had varying efficacy but a large number of new agents are in early phase trials for adults. Areas covered: This review explores the effect of current and potential future paediatric NAFLD treatments in terms of histological and biochemical endpoints. The potential for the extension of adult treatments to children is discussed, as well as what limits the use of certain agents in children. Expert commentary: No drugs have yet to be licenced for NAFLD. Trial heterogeneity makes comparison of drugs between studies challenging. FXR agonists are yet to be trialled in children but may represent a safe and potentially efficacious therapy. Future treatments would likely encompass a multimodal approach that may include bariatric surgery.
Related Concept Videos
Pharmacokinetics in Pediatric Patients: Drug Excretion
Atherosclerosis III: Management
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Pharmacokinetics in Pediatric Patients: Drug Distribution
Nephrotic Syndrome II : Assessment and Medical Management
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

